The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy
Not Applicable
- Conditions
- IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy
- Registration Number
- JPRN-UMIN000027050
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1. Had received the treatment, including IVIg, plasma exchange, or steroid within past three months 2. Has past history of hematological malignancy such as multiple myeloma, Waldenstroms macroglobulinemia, amyloidosis, and lymphoma 3. Had received some sort of immunosuppressive therapy within past six months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method